Krebs Biochemicals and Industries Limited has informed the Exchange regarding Board meeting held on November 04, 2025.
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals reported a significant decline in revenue and widening losses for the quarter and half year ended September 30, 2025. Revenue from operations fell to Rs 416.74 lakhs in Q2 FY26 from Rs 548.09 lakhs in Q2 FY25, a drop of about 24%. For the half year, revenue plunged to Rs 964.83 lakhs from Rs 2,574.42 lakhs, a sharp ~62% decline. The company posted a loss before tax of Rs 614.28 lakhs in Q2 and Rs 1,146.71 lakhs in H1 FY26. The Vizag manufacturing unit remains shut since February 2025 following an order from the Andhra Pradesh Pollution Control Board. Net worth is deeply negative at Rs (14,623.88) lakhs with total borrowings of over Rs 21,000 lakhs. Operating cash flow was negative at Rs (603.21) lakhs for the half year. The statutory auditor issued an unmodified review report.
Shareholders face continued operational distress — the company is loss-making, has a negative net worth, negative operating cash flows, and its main Vizag plant is still shut due to a regulatory order. The H1 revenue collapse of over 60% signals severe business contraction, raising serious going-concern risks for the stock.